预防性术后抗生素在组织扩张器乳房再造中的疗效:倾向评分匹配分析
本研究在倾向评分匹配队列中比较仅接受24小时围手术期抗生素与延长术后抗生素的患者,发现术后抗生素处方率为77.2%,匹配后感染需静脉抗生素(6.9% vs 4.6%,P=0.35)或口服抗生素(11.5% vs 16.1%,P=0.16)发生率无显著差异,非计划再手术(P=0.88)和30天再入院(P=0.19)率相似。多因素调整后,术后抗生素与手术部位感染减少无关(OR 0.5,95%CI -0.3至1.3,P=0.23)。结论指出需要多中心随机试验。
要点
- 术后抗生素处方率达77.2%,但匹配后感染率无显著差异。
- 需静脉抗生素感染率:无抗生素组6.9% vs 抗生素组4.6%(P=0.35)。
- 多因素调整后术后抗生素与手术部位感染减少无关(OR 0.5,95%CI -0.3至1.3)。
核心结论
- 在考虑患者合并症和辅助治疗的倾向评分匹配队列中,组织扩张器乳房再造术后抗生素处方未改善扩张器感染率、再手术率或非计划医疗使用率。
- 这些数据强调需要多中心随机试验来评估组织扩张器乳房再造中抗生素预防的效用。
研究设计与样本
- 倾向评分匹配队列研究,将接受24小时围手术期抗生素的患者按1:3匹配至接受术后抗生素的患者,匹配基于人口学、合并症和治疗因素。
- 共431例接受组织扩张器乳房再造的患者,其中77.2%被处方术后抗生素;348例纳入倾向匹配(无抗生素组87例,抗生素组261例)。
主要发现
- 匹配后,需静脉抗生素的感染发生率无显著差异(无抗生素组6.9% vs 抗生素组4.6%,P=0.35)。
- 匹配后,需口服抗生素的感染发生率无显著差异(无抗生素组11.5% vs 抗生素组16.1%,P=0.16)。
- 非计划再手术率(P=0.88)和30天再入院率(P=0.19)相似。
- 多因素调整后,处方术后抗生素与手术部位感染减少无关(OR 0.5,95%CI -0.3至1.3,P=0.23)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Conflicting evidence exists regarding the utility of prophylactic postoperative antibiotics in tissue expander (TE)-based breast reconstruction. This study evaluated the risk of surgical-site infection between patients receiving 24 hours of perioperative antibiotics alone versus prolonged postoperative antibiotics within a propensity score-matched cohort. METHODS: Patients undergoing TE-based breast reconstruction receiving 24 hours of perioperative antibiotics alone were propensity score-matched 1:3 to patients receiving postoperative antibiotics based on demographics, comorbidities, and treatment factors. Incidence of surgical-site infection was compared based on duration of antibiotic prophylaxis. RESULTS: Of a total of 431 patients undergoing TE-based breast reconstruction, postoperative antibiotics were prescribed in 77.2%. Within this cohort, 348 were included for propensity matching (no antibiotics, 87 patients; antibiotics, 261 patients). After propensity score matching, there was no significant difference in incidence of infection requiring intravenous (no antibiotics, 6.9%; antibiotics, 4.6%; P = 0.35) or oral antibiotics (no antibiotics, 11.5%; antibiotics, 16.1%; P = 0.16). In addition, rates of unplanned reoperation ( P = 0.88) and 30-day readmission ( P = 0.19) were similar. After multivariate adjustment, prescription of postoperative antibiotics was not associated with a reduction in surgical-site infection (OR, 0.5; 95% CI, -0.3 to 1.3; P = 0.23). CONCLUSIONS: Within a propensity score-matched cohort accounting for patient comorbidities and receipt of adjuvant therapies, prescription of postoperative antibiotics after TE-based breast reconstruction conferred no improvement in rates of TE infection, reoperation, or unplanned health care use. These data underscore the need for multicenter randomized trials on the utility of antibiotic prophylaxis in TE-based breast reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Sergesketter AR, Langdell HC, Shammas RL, et al. Efficacy of Prophylactic Postoperative Antibiotics in Tissue Expander-Based Breast Reconstruction: A Propensity Score-Matched Analysis. Plast Reconstr Surg. 2023. PMID: 37335554. doi:10.1097/PRS.0000000000010825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。